<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2135">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04600895</url>
  </required_header>
  <id_info>
    <org_study_id>ATI0220</org_study_id>
    <nct_id>NCT04600895</nct_id>
  </id_info>
  <brief_title>The Prevent Severe COVID-19 (PRESECO) Study</brief_title>
  <acronym>PRESECO</acronym>
  <official_title>Favipiravir for Patients With Mild to Moderate Disease From Novel Coronavirus (COVID-19)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Appili Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Appili Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Double-blinded, placebo control, randomized, phase-3 clinical trial to evaluate clinical&#xD;
      efficacy of Favipiravir in patients with mild to moderate symptoms related to COVID-19&#xD;
      infection&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 30, 2020</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to sustained clinical recovery</measure>
    <time_frame>From Day 0 to Day 28</time_frame>
    <description>The endpoint will be considered to have been met at the earliest time point at which the subject has reached Sustained Alleviation of Symptoms (Symptoms related to smell or taste are not included in the primary endpoint) reported by the patient have reached a severity of &quot;0 - none&quot; or &quot;1 - mild&quot; in assessments for 4-point scale assessments and not known to have redeveloped any COVID-19 associated signs and symptoms (not including reduced sense of taste or smell) in a severity beyond mild for 4 consecutive days when assessed from the start of study treatment to day 28. To meet the primary endpoint, subjects must survive with no hospitalization to day 28.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Patient Reported Global Daily impression</measure>
    <time_frame>From Day 0 to Day 28</time_frame>
    <description>Proportion of patients showing sustained Alleviation of Symptoms by Days 4, 7, 10, 14, 17, 21, 24, and 28, where alleviation is defined as symptom severity of 0 or 1 and is maintained to day 28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients showing sustained resolution of Symptoms</measure>
    <time_frame>Day 4, 7, 10, 14, 17, 21, 24, and 28</time_frame>
    <description>Proportion of patients showing sustained resolution of Symptoms by Days 4, 7, 10, 14, 17, 21, 24, and 28, where resolution is defined as symptom severity of 0 and is maintained to day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to improvement in symptoms</measure>
    <time_frame>Day 0 - 28</time_frame>
    <description>Time (number of days) to improvement in each of the symptoms of stuffy or runny nose, sore throat, shortness of breath, cough, lack of energy or tiredness, muscle or body aches, headache, chills or shivering, feeling hot or feverish, nausea, vomiting, diarrhea by at least 1 grade over baseline (Day 1 Self-Assessment Severity).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients that progress to severe COVID-19</measure>
    <time_frame>Day 28</time_frame>
    <description>Progression to severe COVID-19 (severe COVID-19 defined as O2 saturation of &lt;94% at rest, all cause hospitalization, or death)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in Death Related to COVID-19</measure>
    <time_frame>Day 21</time_frame>
    <description>Proportion of patients dying a. from any cause, b. from a COVID-19 associated complication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in Patient Hospitalization</measure>
    <time_frame>Day 28</time_frame>
    <description>Proportion of patients hospitalized: a. from any cause, b. from a COVID-19 associated complication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in incidence of hospitalization for respiratory distress or O2 saturation</measure>
    <time_frame>Day 28</time_frame>
    <description>Incidence of hospitalization for respiratory distress or O2 saturation &lt;93%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to sustained clinical recovery among SARS-CoV-2 IgG-negative subjects at enrollment from start of study treatment</measure>
    <time_frame>28 days</time_frame>
    <description>Time (number of days) to sustained clinical recovery among SARS-CoV-2 IgG-negative subjects at enrollment from start of study treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to sustained clinical recovery among subjects with ≤3 days of COVID-19 symptoms at enrollment from start of study treatment</measure>
    <time_frame>28 days</time_frame>
    <description>Time (number of days) to sustained clinical recovery among subjects with ≤3 days of COVID-19 symptoms at enrollment from start of study treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to negative conversion of detectable SARS-CoV-2 viral RNA in RT-PCR assays of saliva</measure>
    <time_frame>Day 0 to Day 10</time_frame>
    <description>Time (number of days) to negative conversion of detectable SARS-CoV-2 viral RNA in RT-PCR assays of saliva, from start of study treatment to study day 10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients showing negative conversion of detectable SARS-CoV-2 viral RNA in saliva</measure>
    <time_frame>Days 2, 4, 6, 8 and 10</time_frame>
    <description>Proportion of patients showing negative conversion of detectable SARS-CoV-2 viral RNA in saliva on Study Days 2, 4, 6, 8 and 10</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety / Adverse Events</measure>
    <time_frame>Day 21</time_frame>
    <description>Number (and proportion) of patients reporting treatment emergent adverse events by MedDRA system organ class and preferred term</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">826</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Favipiravir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Favipiravir</intervention_name>
    <description>Favipiravir</description>
    <arm_group_label>Favipiravir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults age 18 or older&#xD;
&#xD;
          -  Tested positive for SARS-CoV-2 by RT-PCR assay using a respiratory tract sample&#xD;
             (either nasopharyngeal swab OR oropharyngeal swab OR nasal aspirate OR&#xD;
             tracheobronchial aspirate OR saliva) collected within 72 hours of randomization&#xD;
&#xD;
          -  Stated willingness to give their written informed consent to participate in the study&#xD;
&#xD;
          -  Stated willingness to comply with all study procedures and availability for the&#xD;
             duration of the study&#xD;
&#xD;
          -  Males must be sterile, OR agree not to donate semen AND agree to strictly adhere to&#xD;
             contraceptive measures during the study and for 7 days following the last dose of&#xD;
             study medication&#xD;
&#xD;
          -  Females must be unable to bear children, OR ensure that their male partner is&#xD;
             incapable of fathering a child, OR, if of childbearing potential will strictly adhere&#xD;
             to contraceptive measures during the study and for seven days following the last dose&#xD;
             of study medication&#xD;
&#xD;
          -  Females must agree to stop breast-feeding prior to first dose of study drug and&#xD;
             through seven days after completing therapy&#xD;
&#xD;
          -  Females must have a negative pregnancy test at screening&#xD;
&#xD;
          -  Ability to take oral medication and be willing to adhere to the favipiravir/placebo&#xD;
             regimen&#xD;
&#xD;
          -  Subject has access to a smart phone, tablet, or PC&#xD;
&#xD;
          -  Minimal baseline severity score for COVID-19-related symptoms: at least two symptoms&#xD;
             with a score of 2 or higher.&#xD;
&#xD;
        COVID-19-related symptoms (excluding changes in the sense of taste or smell) include:&#xD;
&#xD;
          -  stuffy or runny nose&#xD;
&#xD;
          -  sore throat&#xD;
&#xD;
          -  shortness of breath&#xD;
&#xD;
          -  cough&#xD;
&#xD;
          -  lack of energy or tiredness&#xD;
&#xD;
          -  muscle or body aches&#xD;
&#xD;
          -  headache&#xD;
&#xD;
          -  chills or shivering&#xD;
&#xD;
          -  feeling hot or feverish&#xD;
&#xD;
          -  nausea&#xD;
&#xD;
          -  diarrhea&#xD;
&#xD;
          -  vomiting&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  O2 saturation &lt;94%&#xD;
&#xD;
          -  Shortness of breath at rest&#xD;
&#xD;
          -  Heart rate ≥ 125 per minute&#xD;
&#xD;
          -  Requirement for hospitalization at the time of enrolment&#xD;
&#xD;
          -  Participation in another trial or use of any experimental treatment for COVID-19&#xD;
&#xD;
          -  Treatment with high steroid dose (excluding stable chronic treatment) or remdesivir&#xD;
&#xD;
          -  Evidence of sepsis or organ dysfunction/ failure&#xD;
&#xD;
          -  Known infection with a respiratory virus other than SARS-CoV2 (e.g. Influenza) or any&#xD;
             known bacterial infection (affecting the respiratory system or any other system)&#xD;
&#xD;
          -  Inability to adhere to study requirements&#xD;
&#xD;
          -  For premenopausal women: unwilling or unable to use effective birth control measures&#xD;
&#xD;
          -  Known allergy to favipiravir&#xD;
&#xD;
          -  Known end-stage kidney disease or requiring hemodialysis or continuous ambulatory&#xD;
             peritoneal dialysis (CAPD)&#xD;
&#xD;
          -  Liver impairment greater than Child-Pugh A&#xD;
&#xD;
          -  Psychiatric illness that is not well controlled (defined as stable on a regimen for&#xD;
             more than one year).&#xD;
&#xD;
          -  Known elevated uric acid levels in the past year or taking uric acid lowering&#xD;
             medications (allopurinol, febuxostat)&#xD;
&#xD;
          -  History of hereditary xanthinuria or history of xanthine urolithiasis.&#xD;
&#xD;
          -  History of gout or actively being treated for gout.&#xD;
&#xD;
          -  Current use of the following medications, which cannot be discontinued for the&#xD;
             duration of the study: pyrazinamide, hydralazine, more than 3000 mg of acetaminophen&#xD;
             per day.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Prasann Bavaniya, MSc BT</last_name>
    <phone>+1 902 442 4655</phone>
    <phone_ext>7, 5</phone_ext>
    <email>pbavaniya@appilitherapeutics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cahaba Research, Inc.</name>
      <address>
        <city>Pelham</city>
        <state>Alabama</state>
        <zip>35124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Absolute Clinical Research</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85051</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>B.G Clinical Research Center, LLC</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Xera Med Research</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33487</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Synergy Healthcare</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Best Quality Research,Inc.</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Elixia Clinical Research Collaborative</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33023</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neil Patel</last_name>
      <phone>561-351-7822</phone>
      <email>npatel@elixiacrc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Homestead Associates In Research</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Verus Clinical Research Corporation</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33125</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Quality Professional HealthCare</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Continental Clinical Research, LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Global Life Research Network, Llc</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sanitas Research, LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>US Associates in Research, LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33175</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Biore'Search Institute Llc</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33026</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Luminous Clinical Research - South Florida Urgent Care</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alliance Clinical Research of Tampa</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33615</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Massachusettts Medical School</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Frontier Clinical Research, LLC</name>
      <address>
        <city>Scottdale</city>
        <state>Pennsylvania</state>
        <zip>15683</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Frontier Clinical Research, LLC</name>
      <address>
        <city>Smithfield</city>
        <state>Pennsylvania</state>
        <zip>15478</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>New Phase Research &amp; Development</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37909</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Network</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77074</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Frontier Clinical Research</name>
      <address>
        <city>Kingwood</city>
        <state>West Virginia</state>
        <zip>26537</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>September 15, 2020</study_first_submitted>
  <study_first_submitted_qc>October 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2020</study_first_posted>
  <last_update_submitted>March 23, 2021</last_update_submitted>
  <last_update_submitted_qc>March 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

